Press Releases

Sign up for Email Alerts Press Release RSS

08/20/2018
Bristol-Myers Squibb-Pfizer Alliance ACROPOLIS™ Real-World Data Program Grows to Sample Size of Nearly One Million Lives Worldwide
Term:Corporate/Financial News
Language:English
08/17/2018
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as the First New Medication in Nearly 20 Years for Certain Patients with Previously Treated Small Cell Lung Cancer
Term:Corporate/Financial News
Language:English
07/31/2018
European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection
Term:Corporate/Financial News
Language:English
07/26/2018
Bristol-Myers Squibb Reports Second Quarter Financial Results
Term:Corporate/Financial News
Language:English
07/24/2018
Bristol-Myers Squibb and Tsinghua University Announce Collaboration to Accelerate Early Research into Potential Therapies for Autoimmune Diseases and Cancer
Term:Partnering News
Language:English
07/23/2018
Bristol-Myers Squibb Announces Departure of Chief Commercial Officer
Term:
Language:English
07/11/2018
Bristol-Myers Squibb’s Opdivo® (nivolumab) + Low-Dose Yervoy® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and...
Term:Corporate/Financial News
Language:English
07/05/2018
European Commission Approves Expanded Indication for Sprycel (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Term:Opdivo
Language:English
06/29/2018
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma
Term:$BMY
Language:English
06/21/2018
U.S. Food and Drug Administration (FDA) Accepts Application for Opdivo Plus Low-Dose Yervoy for Treatment of First-Line Non-Small Cell Lung Cancer in Patients with Tumor Mutational Burden ≥10 mut/Mb
Term:Corporate/Financial News
Language:English

Business Wire NewsHQ^sm